atracurium Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
neuromuscular blocking agents with rigid structure 259 64228-79-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • atracurium
  • tracrium
  • atracurium besylate
A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.
  • Molecular weight: 929.16
  • Formula: C53H72N2O12
  • CLOGP: 3.50
  • LIPINSKI: 2
  • HAC: 14
  • HDO: 0
  • TPSA: 126.44
  • ALOGS: -7.63
  • ROTB: 26

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 0 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 8.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.65 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 0.10 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 5.70 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.52 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.31 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 23, 1983 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 275.73 138.47 52 355 4234 2353444
Hypotension 184.21 138.47 55 352 32381 2325297
Anaphylactic reaction 173.69 138.47 41 366 9664 2348014

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Bronchospasm 179.37 109.58 33 247 2049 1744452
Anaphylactic reaction 154.83 109.58 35 245 6078 1740423
Anaphylactic shock 144.08 109.58 29 251 2870 1743631

Pharmacologic Action:

SourceCodeDescription
ATC M03AC04 MUSCULO-SKELETAL SYSTEM
MUSCLE RELAXANTS
MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS
Other quaternary ammonium compounds
FDA PE N0000175732 Neuromuscular Nondepolarizing Blockade
FDA EPC N0000175720 Nondepolarizing Neuromuscular Blocker
MeSH PA D018678 Cholinergic Agents
MeSH PA D018680 Cholinergic Antagonists
MeSH PA D009465 Neuromuscular Agents
MeSH PA D009466 Neuromuscular Blocking Agents
MeSH PA D003473 Neuromuscular Nondepolarizing Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018733 Nicotinic Antagonists
MeSH PA D018373 Peripheral Nervous System Agents
CHEBI has role CHEBI:51371 muscle relaxant
CHEBI has role CHEBI:48878 nicotinic antagonist

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Muscle relaxation, function indication 11977004
General anesthesia indication 50697003
Skeletal Muscle Relaxation for Endotracheal Intubation indication
Hypocalcemia contraindication 5291005
Disorder of lung contraindication 19829001 DOID:850
Hypokalemia contraindication 43339004
Low blood pressure contraindication 45007003
Eaton-Lambert syndrome contraindication 56989000 DOID:0050214
Hypermagnesemia contraindication 66978005
Myasthenia gravis contraindication 91637004 DOID:437
Disorder of electrolytes contraindication 237840007
Hypothermia contraindication 386689009
Malignant hyperthermia contraindication 405501007

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Acetylcholine receptor Ion channel ANTAGONIST IC50 7.77 WOMBAT-PK CHEMBL
Neuronal acetylcholine receptor subunit alpha-2 Ion channel WOMBAT-PK
Small conductance calcium-activated potassium channel protein 3 Ion channel Ki 5.23 CHEMBL

External reference:

IDSource
D001279 MESH_DESCRIPTOR_UI
4019619 VUID
N0000147713 NUI
C0004234 UMLSCUI
D00758 KEGG_DRUG
40AX66P76P UNII
4734 INN_ID
64228-81-5 SECONDARY_CAS_RN
74074008 SNOMEDCT_US
4019619 VANDF
1218 RXNORM
372835000 SNOMEDCT_US
d00173 MMSL
013420 NDDF
CHEMBL1360 ChEMBL_ID
DB00732 DRUGBANK_ID
CHEMBL1200527 ChEMBL_ID
CHEBI:2914 CHEBI
9537 IUPHAR_LIGAND_ID
47319 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Atracurium Besylate HUMAN PRESCRIPTION DRUG LABEL 1 0409-1105 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 12 sections
Atracurium Besylate HUMAN PRESCRIPTION DRUG LABEL 1 0409-1109 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 12 sections
Atracurium Besylate HUMAN PRESCRIPTION DRUG LABEL 1 25021-659 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 12 sections
Atracurium Besylate HUMAN PRESCRIPTION DRUG LABEL 1 25021-672 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 12 sections
Atracurium Besylate HUMAN PRESCRIPTION DRUG LABEL 1 55150-216 INJECTION, SOLUTION 50 mg INTRAVENOUS ANDA 12 sections
Atracurium Besylate HUMAN PRESCRIPTION DRUG LABEL 1 55150-217 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 12 sections
Atracurium Besylate HUMAN PRESCRIPTION DRUG LABEL 1 71288-701 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 12 sections
Atracurium Besylate HUMAN PRESCRIPTION DRUG LABEL 1 71288-702 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 12 sections